Skip to Content

Casimersen Approval Status

FDA Approved: No
Generic name: casimersen
Company: Sarepta Therapeutics
Treatment for: Duchenne Muscular Dystrophy

Casimersen is a phosphorodiamidate morpholino oligomer in development for the treatment of patients with Duchenne muscular dystrophy (DMD) who have genetic mutations that are amenable to skipping exon 45 of the Duchenne gene.

Development Status and FDA Approval Process for casimersen

DateArticle
Jun 26, 2020Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.